SciClone research finds oral version of SCV-07 as effective as injection against TB in animals

New York, June 5 - SciClone Pharmaceuticals, Inc. reported preclinical data showing that the oral formulation of SCV-07 was as effective against tuberculosis as the standard injection formulation in an animal model study.

Twelve days after infection with M. tuberculosis Erdman, mice were treated with isoniazid and rifampicin, and some were further treated for five days with either oral or intraperitoneally injected SCV-07 at doses ranging from 0.10 to 10 ug/kg. Forty five days later, pathological signs of tuberculosis were evaluated, and both the oral and injected groups demonstrated significant improvement when treated with 1.0 ug/kg of SCV-07, compared to the control group, which showed minimal changes, the company said.

SciClone added that it has a phase 1 trial under way in healthy human volunteers. Results are expected in the second half.

If successful, the San Mateo, Calif., biopharmaceutical company said an oral version could "substantially broaden the therapeutic potential for SCV-07."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.